Bimekizumab versus Adalimumab in Plaque Psoriasis | Zendy

Richard B. Warren | Zendy; Andrew Blauvelt | Zendy; Jerry Bagel | Zendy; Kim Papp | Zendy; Paul S. Yamauchi | Zendy; April W. Armstrong | Zendy; Richard Langley | Zendy; Veerle Vanvoorden | Zendy; Dirk De Cuyper | Zendy; Christopher L. Cioffi | Zendy; Luke Peterson | Zendy; Nancy Cross | Zendy; Kristian Reich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bimekizumab versus Adalimumab in Plaque Psoriasis

Author(s) -

Richard B. Warren,

Andrew Blauvelt,

Jerry Bagel,

Kim Papp,

Paul S. Yamauchi,

April W. Armstrong,

Richard Langley,

Veerle Vanvoorden,

Dirk De Cuyper,

Christopher L. Cioffi,

Luke Peterson,

Nancy Cross,

Kristian Reich

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2102388

Subject(s) - adalimumab , plaque psoriasis , psoriasis , medicine , monoclonal antibody , tumor necrosis factor alpha , monoclonal , tumor necrosis factor α , interleukin 17 , interleukin , dermatology , immunology , antibody , inflammation , cytokine

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research